The Experts below are selected from a list of 291 Experts worldwide ranked by ideXlab platform
Chor Sang Chim - One of the best experts on this subject based on the ideXlab platform.
-
Establishment of a bortezomib-resistant Chinese human multiple Myeloma Cell Line: MMLAL
Cancer Cell International, 2013Co-Authors: Kwan Yeung Wong, Chi Chiu So, Chor Sang ChimAbstract:Background A new human Myeloma Cell Line, MMLAL, was established from the Myelomatous pleural effusion of a 73-year-old Chinese patient suffering from symptomatic International stage III IgG/lambda Myeloma. After a brief period of complete remission, he developed aggressive systemic relapse complicated by malignant pleural effusion with exclusive plasma Cell infiltration. His disease remained chemo-refractory, and died six months after relapse.
-
establishment of a bortezomib resistant chinese human multiple Myeloma Cell Line mmlal
Cancer Cell International, 2013Co-Authors: Kwan Yeung Wong, Chi Chiu So, Chor Sang ChimAbstract:Background: A new human Myeloma Cell Line, MMLAL, was established from the Myelomatous pleural effusion of a 73-year-old Chinese patient suffering from symptomatic International stage III IgG/lambda Myeloma. After a brief period of complete remission, he developed aggressive systemic relapse complicated by malignant pleural effusion with exclusive plasma Cell infiltration. His disease remained chemo-refractory, and died six months after relapse. Methods: Purified mononuclear Cells from the pleural effusion of the patient were cultured in the presence of IL-6. Continually growing Cells were characterized by morphological, immunophenotypic, cytogenetic, fluorescence in situ hybridization (FISH) and TP53 mutation analyses. Cell proliferation was measured and compared with other Myeloma Cell Lines by Cell counting at day 3, 6, 9, and 12. Drug resistance against bortezomib, a proteasome inhibitor approved as a frontLine chemotherapy for eligible Myeloma patients, was evaluated and compared with other Myeloma Cell Lines by MTT assay. Results: Immunophenotypic analysis of the Myeloma Cells confirmed strong expression of plasma Cell markers CD38 and CD138 but not T-Cell or natural killer-Cell marker CD56. Cytogenetic analysis of the Myeloma Cells showed a hypodiploid composite karyotype including loss of chromosome 13 and 17 or deletion of the short arm of chromosome 17, i.e. del(17p), in the form of isochromosome 17q10. FISH confirmed a hypodiploid karyotype with TP53 deletion but absence of t(4;14). Sequencing analysis of the TP53 gene indicated absence of mutation. Cell counting revealed that the maximum viable Cell density was about 2.5 X 10 6 Cells/ml. Upon bortezomib treatment, MTT assay reported an IC50 of 72.17nM, suggesting a strong bortezomib resistance. Conclusion: A hypodiploid with loss of chromosome 13 and loss or del(17p) human Myeloma Cell Line, MMLAL, was established from the pleural effusion of a Chinese Myeloma patient.
Kwan Yeung Wong - One of the best experts on this subject based on the ideXlab platform.
-
Establishment of a bortezomib-resistant Chinese human multiple Myeloma Cell Line: MMLAL
Cancer Cell International, 2013Co-Authors: Kwan Yeung Wong, Chi Chiu So, Chor Sang ChimAbstract:Background A new human Myeloma Cell Line, MMLAL, was established from the Myelomatous pleural effusion of a 73-year-old Chinese patient suffering from symptomatic International stage III IgG/lambda Myeloma. After a brief period of complete remission, he developed aggressive systemic relapse complicated by malignant pleural effusion with exclusive plasma Cell infiltration. His disease remained chemo-refractory, and died six months after relapse.
-
establishment of a bortezomib resistant chinese human multiple Myeloma Cell Line mmlal
Cancer Cell International, 2013Co-Authors: Kwan Yeung Wong, Chi Chiu So, Chor Sang ChimAbstract:Background: A new human Myeloma Cell Line, MMLAL, was established from the Myelomatous pleural effusion of a 73-year-old Chinese patient suffering from symptomatic International stage III IgG/lambda Myeloma. After a brief period of complete remission, he developed aggressive systemic relapse complicated by malignant pleural effusion with exclusive plasma Cell infiltration. His disease remained chemo-refractory, and died six months after relapse. Methods: Purified mononuclear Cells from the pleural effusion of the patient were cultured in the presence of IL-6. Continually growing Cells were characterized by morphological, immunophenotypic, cytogenetic, fluorescence in situ hybridization (FISH) and TP53 mutation analyses. Cell proliferation was measured and compared with other Myeloma Cell Lines by Cell counting at day 3, 6, 9, and 12. Drug resistance against bortezomib, a proteasome inhibitor approved as a frontLine chemotherapy for eligible Myeloma patients, was evaluated and compared with other Myeloma Cell Lines by MTT assay. Results: Immunophenotypic analysis of the Myeloma Cells confirmed strong expression of plasma Cell markers CD38 and CD138 but not T-Cell or natural killer-Cell marker CD56. Cytogenetic analysis of the Myeloma Cells showed a hypodiploid composite karyotype including loss of chromosome 13 and 17 or deletion of the short arm of chromosome 17, i.e. del(17p), in the form of isochromosome 17q10. FISH confirmed a hypodiploid karyotype with TP53 deletion but absence of t(4;14). Sequencing analysis of the TP53 gene indicated absence of mutation. Cell counting revealed that the maximum viable Cell density was about 2.5 X 10 6 Cells/ml. Upon bortezomib treatment, MTT assay reported an IC50 of 72.17nM, suggesting a strong bortezomib resistance. Conclusion: A hypodiploid with loss of chromosome 13 and loss or del(17p) human Myeloma Cell Line, MMLAL, was established from the pleural effusion of a Chinese Myeloma patient.
Simon J. Gaskell - One of the best experts on this subject based on the ideXlab platform.
-
Proteomic analysis of the adaptation of the host NS0 Myeloma Cell Line to a protein-free medium
2020Co-Authors: Kathya R De La Luz-hernández, Luis Rojas-del Calvo, Svieta Victores-sarasola, Agustín Lage-castellanos, Claire E. Eyers, Sarah R. Hart, Lila Castellanos-serra, Adolfo Castillo-vitlloch, Simon J. Gaskell, Michael BarberAbstract:The NS0 Myeloma Cell Line is often used for the production of monoclonal antibodies (Mabs) and other recombinant proteins. The growth of these mammalian Cells in a protein-free media has several advantages including cost, safety, consistency, efficiency and regulatory approval. However, the adaptation of the NS0 Myeloma Cell Line so as to grow in a protein-free medium is poorly understood. In order to better understand this process, we applied proteomic techniques, specifically two-dimensional electrophoresis (2DE) and mass spectrometry (MS), to identify the key pathways involved in this adaptation. The analysis of changes in protein expression between the host Myeloma Cell Line and two recombinant NS0 Cell Lines expressing different humanized Mabs has primarily revealed changes in proteins associated with carbohydrate metabolism, energy production, protein synthesis and folding, membrane transport and Cell proliferation. Other factors that may be involved in the adaptation of NS0 Myeloma Cells to a protein-free medium are reported.
-
Using the “OMICS” Technologies as Complementary Tools to Study the Molecular Mechanisms Involved with the Adaptation of Myeloma Cell Line to Protein-Free Medium
Proceedings of the 21st Annual Meeting of the European Society for Animal Cell Technology (ESACT) Dublin Ireland June 7-10 2009, 2011Co-Authors: Kathya R De La Luz-hernández, Agustín Lage-castellanos, Lila Castellanos-serra, Adolfo Castillo-vitlloch, Y. Rabasa-legón, J. Díaz-brito, Simon J. GaskellAbstract:Production of recombinant therapeutic proteins, especially monoclonal antibodies (Mab), in Myeloma Cell Lines represents a significant segment of the pharmaceutical market, and therefore striving for increased productivity of these Lines represents a major investment of resources. The elucidation of biologically important markers for the adaptation of NS0 Myeloma Cell Line to protein-free medium and the recombinant protein production are a major emphasis of our research. These markers could potentially be used in a variety of ways to improve culture conditions, including active approaches to agonize/antagonize important pathways within a medium formulation or diagnostic approaches indicative of improved conditions during the culture. In this work, we used two-dimensional electrophoresis/mass spectrometry and the iTRAQ technology to analyze different protein levels in adapted and non-adapted NS0 Myeloma Cell Line. Several proteins with differential expression profile were characterized and quantified. Changes in lactate production rate with respect to glucose consumption rate were observed according to the changes observed by proteomic. Carbohydrate metabolism, protein synthesis and membrane transport were the principal pathways that change after the adaptation by proteomic analysis. The same results were obtained using flux balance analysis in a murine metabolic network with selected medium conditions.
-
metabolic and proteomic study of ns0 Myeloma Cell Line following the adaptation to protein free medium
Journal of Proteomics, 2008Co-Authors: K R De La Luzhernandez, Rojasdel L Calvo, Y Rabasalegon, A Lagecastellanos, A Castillovitlloch, J Diaz, Simon J. GaskellAbstract:Abstract Proteomics and metabolomics technologies are potentially useful tool for the study of the very complex process of Cell adaptation to protein-free medium. In this work, we used the iTRAQ technology to analyze different protein levels in adapted and non-adapted NS0 Myeloma Cell Line. Several proteins with differential expression profile were characterized and quantified. Carbohydrate metabolism, protein synthesis and membrane transport were the principal pathways that change after the adaptation. Changes in lactate production rate with respect to glucose consumption rate were observed according to the changes observed by proteomic.
K R De La Luzhernandez - One of the best experts on this subject based on the ideXlab platform.
-
metabolic and proteomic study of ns0 Myeloma Cell Line following the adaptation to protein free medium
Journal of Proteomics, 2008Co-Authors: K R De La Luzhernandez, Rojasdel L Calvo, Y Rabasalegon, A Lagecastellanos, A Castillovitlloch, J Diaz, Simon J. GaskellAbstract:Abstract Proteomics and metabolomics technologies are potentially useful tool for the study of the very complex process of Cell adaptation to protein-free medium. In this work, we used the iTRAQ technology to analyze different protein levels in adapted and non-adapted NS0 Myeloma Cell Line. Several proteins with differential expression profile were characterized and quantified. Carbohydrate metabolism, protein synthesis and membrane transport were the principal pathways that change after the adaptation. Changes in lactate production rate with respect to glucose consumption rate were observed according to the changes observed by proteomic.
Jeffrey M Trent - One of the best experts on this subject based on the ideXlab platform.
-
development and characterization of a melphalan resistant human multiple Myeloma Cell Line
Cancer Research, 1991Co-Authors: William T Bellamy, William S Dalton, Mary C Gleason, Thomas M Grogan, Jeffrey M TrentAbstract:Abstract We present data describing a human Myeloma Cell Line (8226/LR-5) selected for resistance to melphalan which exhibits a 7-fold level of resistance to melphalan and is partially cross-resistant to other bifunctional alkylators and X-irradiation. Melphalan resistance is relatively unstable with a decrease in resistance observed within 17 weeks in the absence of drug. The resistance observed in this Cell Line is not mediated by reduced intraCellular melphalan accumulation. DNA interstrand cross-linking at equivalent intraCellular drug accumulation is significantly reduced in the resistant subLine. Whether this reduction is the result of a decrease in the formation of this lesion or to an increased rate of removal of the lesion remains to be determined. Growth characteristics and Cell cycle kinetics, including S phase, were similar between sensitive and resistant Cell Lines. IntraCellular nonprotein thiols were found to be significantly elevated in the resistant 8226/LR-5 Cells; as Cells revert or lose resistance, intraCellular nonprotein sulfhydryl levels decLine. Prior treatment of the Cells with buthionine sulfoximine significantly reduced nonprotein sulfhydryl levels and enhanced melphalan cytotoxicity in both the sensitive and resistant Cell Lines. Thiols appear to play a role in mediating melphalan resistance.
